Takeda, a large pharmaceutical company, announced that Julie Kim will become its new CEO in June 2026. She will take over from Christophe Weber, who has been the CEO since 2014.
Julie Kim is currently the president of Takeda’s Plasma-Derived Therapies division. She has been with the company since 2019 and has helped grow the plasma business, which makes important medicines from blood plasma.
Christophe Weber will continue to lead the company until June 2026 to ensure a smooth transition. He will then become the chairman of Takeda’s board.
This change marks an important step for Takeda as they continue to develop new medicines and expand globally. Julie Kim’s leadership is expected to help the company grow even more in the future.
Please See Here